Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a a list published by the National Healthcare Security Administration showed on Monday.
https://finance.yahoo.com/healthcare/articles/pfizer-innovent-glp-1-drugs-051957167.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.